Immunic, Inc. Announces Positive Top-Line Data From Investigator- Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Immunic, Inc. Announces Positive Top-Line Data From Investigator- Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

– Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline –

– Primary Objective of Therapeutic Benefit Achieved in 27.3% of the Patients of the Per-Protocol Population at Week 24 –

– Other Liver Biochemistry Parameters Remained Stable –

– IMU-838’s Favorable Safety and Tolerability Profile Confirmed in This Patient Population –

– Study Conducted in Collaboration with Investigators at Mayo Clinic in Arizona and Minnesota –

Please see the link below to the full article

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis